The Office of Patented Medicines and Liaison of Health Canada recently released its Statistical Report for the fiscal year ending March 31, 2023. It encompasses information related to Patented Medicines (Notice of Compliance) Regulations, Data Protection (C.08.004.1 of the Food and Drug Regulations), and Certificates of Supplementary Protection.
This document, released on June 23, 2023, continues a series of such report publications aiming to provide necessary information to professionals, stakeholders and analysts.
Within the detailed assessment, the document breaks down the significant developments and trends in the pharmaceutical and legal sectors over the period covered by the report. It scrutinizes the contributions of the Patented Medicines (Notice of Compliance) Regulations, the stipulations of the Data Protection sections under Food and Drug Regulations, and the influence of Certificates of Supplementary Protection on the sector.
Notably, similar to previous publications, the incorporation of diverse information has remained a hallmark of the report. It extends insight into the interface of law, health, and the pharmaceutical industry, thereby offering a comprehensive overview of the interdependencies of these areas.
As we progress through an epoch characterized by an increasing emphasis on data protection, patented medicines, and supplementary protection, this document serves as a valuable recourse to legal professionals working within the sphere of pharma, healthcare, and related industries.
The report, courtesy of Smart & Biggar, is accessible in its entirety via the link provided above. Long-term engagement with these statistical reports continues to be instrumental in understanding trends, gauging future trajectories, and gaining an enriched perspective on the landscape of pharmaceutical regulations and related legal determinants.